Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
Lu, T.-M
Now its time to get it in your body
Results are shown as fold changes relative to the control condition without histidine (zero)
US$ 25.34
-1775582746855.png&w=3840&q=75)
US$ 28.57
US$ 26.35
US$ 29.62
US$ 28.04
:max_bytes(150000):strip_icc()/VWH-GettyImages-2059065209-7ab09bdd0be8409493ace4364fccf792.jpg)
US$ 23.99
